Stock Ratings / Health Care / JNJ / financials

ABBV (81) MRK (75) NVS (66) AZN (62) ⌘ Pro Terminal →

Johnson & Johnson (JNJ) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$273.20 -0.73% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $273.50

Johnson & Johnson (JNJ) earns a Roarable Rating of A- (Buy) with 82/100 RQD Confidence. High-quality cash engine (68% profit margin, 26% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 82/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.6% avg 90D alpha vs SPY • 71.9% hit rate) →

ROARABLE A- • BUY Cap $662.49B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on JNJ Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is JNJ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Johnson & Johnson (NYSE: JNJ) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $273.20 (-0.73% 1D, market cap $662.49B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, JNJ ranks #8 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does JNJ compare to ABBV and MRK in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JNJ carries a Roarable A- (82/100 RQD), trailing P/E of 24.7x, gross margin of 67.9%, and ROIC of 25.5%. By comparison, ABBV (AbbVie Inc.) holds a A- grade (81/100 RQD, P/E 121.6x, ROIC 29.0%, cap $513.86B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for JNJ?

▼

Per JNJ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000200406), Johnson & Johnson generated $94.19B in revenue (+6.0% YoY), $26.80B in net income, and $19.70B in free cash flow against $199.21B in total assets and $39.44B in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $273.50 (+0.11%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 20.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 82/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.6% avg 90D alpha vs SPY • 71.9% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • A-

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JNJ)Realized 20D OHLCV Swing Band: ±5%

Deterministic 5-Pillar Attribution (82/100 Composite)

🔍 WHY JNJ SCORES 82/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (22% of score)

20D Institutional Volume Accumulation (±5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (22% of score)

Altman Z-Score 5.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution15/20 pts (-5 pt drag)

Cannibal Buyback (-2.08% YoY Shares) & executive Form 4 sales trim 5 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$248.61+4.3% Next Q

Q2 (-2Q)

Grade B+$259.36+3.6% Next Q

Q3 (-1Q)

Grade A-$268.73+1.7% Next Q

Current

Grade A-$273.20+8.6% Hist 90D α

Trajectory: B+ (74) → A- (82)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the JNJ Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 82/100 (A-) score, JNJ faces multiple-compression risk if 24.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 65.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($265.74) or 200D SMA ($247.55) invalidates the momentum regime and cuts Target Base ($302.71) toward Bear Floor ($224.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JNJ• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “JNJ Beats Next Quarter EPS Consensus (Dec 27, 2026) & Holds Above 200D SMA”

YES 82%NO 18%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How JNJ Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$19.70B (20.9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $85.16B

FY24

Rev $88.82B

FY25

Rev $94.19B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$94.19B	67.9%	33.6%	$26.80B	$19.70B	24.7%
FY 2024	$88.82B	69.1%	18.7%	$14.07B	$19.84B	16.8%
FY 2023	$85.16B	67.9%	48.7%	$35.15B	$18.96B	14.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JNJ)

✓Walkthrough of JNJ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

JNJ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.86%📐 HORIZONTAL RANGE

2026-11-02O $271.0H $275.2L $271.0C $273.2VOL 6.02M

RES: $282.1SUP: $243.6SMA50: $265.7SMA200: $247.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JNJ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JNJ Butterfly Map → + Track JNJ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.4%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on JNJ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JNJ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for JNJ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JNJ)

Health Care Rank #8 of 1016 ⚔️ ABBV vs JNJ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JNJ vs. ABBV, MRK, NVS, AZN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Johnson & Johnson (JNJ) ranks #8 by composite RQD confidence (82/100, grade A-) and #2 by equity capitalization ($662.49B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. JNJ currently leads its immediate peer cohort in composite quantitative strength at 82/100 (A-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
JNJ ACTIVE Johnson & Johnson	A-	82/100	24.7x	67.9%	25.5%	-0.73%	$662.49B	Benchmark Subject
ABBV AbbVie Inc.	A-	81/100	121.6x	70.2%	29.0%	+1.41%	$513.86B	/abbv-vs-jnj →
MRK Merck & Company Inc.	B	75/100	19.8x	74.8%	20.7%	+2.18%	$361.02B	/mrk-vs-jnj →
NVS Novartis AG	C+	66/100	32.8x	—	9.9%	-0.19%	$307.40B	/nvs-vs-jnj →
AZN AstraZeneca PLC	C	62/100	32.8x	—	9.9%	+7.02%	$270.45B	/azn-vs-jnj →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0000200406

In its most recent audited fiscal period (FY2025, filed 2025-12-28), Johnson & Johnson (JNJ) reported GAAP revenue of $94.19B (+6.0% vs. FY2024 revenue of $88.82B , and +10.6% cumulative change since FY2023) , GAAP net income of $26.80B, operating cash flow of $24.53B, and free cash flow of $19.70B (-0.7% YoY). On the balance sheet, JNJ closed FY2025 with $199.21B in total assets against $39.44B in total debt (Altman Z-Score: 5.59, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-28	$94.19B	$26.80B	$24.53B	$19.70B	$199.21B	$39.44B
FY2024 (FY)	2024-12-29	$88.82B	$14.07B	$24.27B	$19.84B	$180.10B	$30.65B
FY2023 (FY)	2023-12-31	$85.16B	$35.15B	$22.79B	$18.96B	$364.37B	$85.26B

3. JNJ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JNJ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does JNJ compare to ABBV and MRK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for JNJ?

Where is JNJ trading relative to its 50-day, 200-day, and 52-week technical levels?

JNJ last traded at $273.20 (-0.73% on volume of 8,969,509 shares), positioning the stock +2.81% above its 50-day simple moving average ($265.74) and +10.36% above its 200-day simple moving average ($247.55). Across its 52-week range of $185.12 to $282.02, JNJ sits at the 90.9% percentile with a 14-day RSI of 62.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($259.54 to $286.86).

JNJ Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Johnson & Johnson (JNJ)?

In FY 2025 (10-K), JNJ converted $94.2B of revenue into a 67.9% gross margin, 33.6% operating margin, and $19.7B in free cash flow (20.9% FCF margin).

Direct Sub-Reports: JNJ RQD Cockpit JNJ 12M Forecast JNJ Earnings & Move JNJ Dividends & DRIP JNJ Insiders & 13F JNJ Whale Options JNJ Profit Sankey JNJ News & Why

Sector Peer Dials

JNJ Core Snapshot

Market Cap $662.49B

Trailing / Fwd P/E 24.7x / 23.0x

Gross Profit Margin 67.9%

Return on Capital (ROIC) 25.5%

Free Cash Flow Yield 2.97%

12M Base Price Target $302.71

FREE TRADER TOOLS

Own JNJ Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With JNJ → 🏆 Trade JNJ in $100K Prop Arena →

JNJ Wire

Why It Moved →

Peer / Ecosystem Wire Yahoo Finance • 5h ago

Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit

Peer / Ecosystem Wire CNBC • 8h ago

J&J posts weak medical device sales, shares fall

Peer / Ecosystem Wire The Motley Fool • 11h ago

Why Johnson & Johnson Stock Dropped Today

Peer / Ecosystem Wire Barron's • 14h ago

Johnson &Johnson Stock Earnings: Can a Spinoff Fix Its Medtech Problem

Peer / Ecosystem Wire Trefis • 17h ago

The Open Question Under Johnson & Johnson Stock’s Price

ROARABLE RATING BRIEF • RQD 82/100 (A-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

JNJ — Johnson & Johnson: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:08:46Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, JNJ scores 82 out of 100, a letter grade of A-, with the verdict label "Roarable Buy — Superior Risk/Reward." The five pillars are: Fundamental Cash Engine at 15/20 (ROIC 25.5%; FCF yield 2.97%); Whale 13F Flow at 18/20 (institutional accumulation and options positioning); Insider Conviction at 15/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 16/20 (Beta 1.08; sector sensitivity); and Forensic Balance Sheet at 18/20 (Altman Z 5.59; Piotroski F 8/9; Debt/Equity 0.48).

For a prospective investor, the strongest pillars are Whale 13F Flow and Forensic Balance Sheet, both at 18/20. The balance-sheet pillar suggests financial-distress risk is low on the metrics cited. The weakest-scoring pillars, Fundamental Cash Engine and Insider Conviction at 15/20 each, are the areas where the case is comparatively less complete. The free-cash-flow yield of 2.97% is a valuation tradeoff: it implies a meaningful premium is being paid for cash generation relative to the price, which the verdict label weighs against the quality metrics. Macro sensitivity is moderate, with a beta of 1.08 indicating slightly higher market sensitivity than the broad market. This brief is analytical and educational and does not constitute personalized financial advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
275.2	$662.49B	24.7	23	18.5	11.13	0%	1.08	$185.12 - $282.02	25.5%

Recent Catalysts & News Wire Analysis

The news wire contains six headlines, all relating to Johnson & Johnson (JNJ). Three are flagged RED / RISK WATCH: a Yahoo Finance report that the stock fell despite strong earnings as investors focused on the medtech unit; a CNBC report on weak medical device sales with shares falling; and a Motley Fool report on the day's drop. Three are flagged YELLOW / MARKET WIRE: a Barron's piece asking whether a spinoff can fix the medtech problem; a Trefis piece on the open question under the stock price; and an Investopedia piece on expected post-earnings move. The recurring theme across the wire is medtech unit weakness, with a spinoff discussed as a possible remedy. The Butterfly Supply-Chain Graph reports no proprietary signals and no links.

Open Questions

What is the segment-level revenue and profit breakdown, particularly for the medtech unit referenced in the news wire?
What is the status and timeline of the spinoff discussed in the Barron's headline, and what would it change for the consolidated financials?
Why are EPS and FY 2023 cash not reported in the financial data, and how would per-share results compare with the net-income trend?
What specific institutional, insider, and Congressional transactions underpin the 18/20 whale and 15/20 insider pillar scores?
What analyst consensus, price targets, and rating distribution apply to JNJ?

JNJ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Johnson & Johnson (JNJ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to JNJ Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 5h ago

Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit

Yahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH CNBC • 8h ago

J&J posts weak medical device sales, shares fall

CNBC report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH The Motley Fool • 11h ago

Why Johnson & Johnson Stock Dropped Today

The Motley Fool report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Barron's • 14h ago

Johnson &Johnson Stock Earnings: Can a Spinoff Fix Its Medtech Problem

Barron's report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 17h ago

The Open Question Under Johnson & Johnson Stock’s Price

Trefis report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investopedia • 20h ago

Here’s How Much Johnson & Johnson Stock Is Expected to Move After Earnings

Investopedia report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 23h ago

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

Yahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Johnson & Johnson Stock Has Surged 44%, Can Its Growth Justify the Valuation?

Yahoo Finance report covering Johnson & Johnson (JNJ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

JNJ Bull vs. Bear Conversation Board — What's Your Call at $273.20?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JNJ 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $324.74 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is JNJ (A- • RQD 82/100) a Buy at $275.20?

Welcome to the JNJ (Johnson & Johnson) Roar Pit. Current RQD Composite is 82/100 (Roarable Buy — Superior Risk/Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (25.5% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $222.91 (-19.0%)

Spot @ $275.20

Pump the brakes on JNJ — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on JNJ, but look at what you are paying: 24.7x trailing P/E with 67.9% gross margins. Unless Johnson & Johnson expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $335.74 (+22.0%)

Spot @ $275.20

JNJ cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on JNJ, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $275.20 (52-wk range $185.12 - $282.02), any beat on forward guidance forces shorts and underweight funds to chase.